• Patricia O Guimarães, Renato D Lopes, Daniel M Wojdyla, John H Alexander, Shaun G Goodman, Ronald Aronson, Sigrun Halvorsen, Peter Sinnaeve, Dragos Vinereanu, Robert F Storey, Otavio Berwanger, Stephan Windecker, Roxana Mehran, Christopher B Granger, Karen P Alexander, and AUGUSTUS Investigators.
• Duke Clinical Research Institute, Duke University School of Medicine, Durham, NC; Hospital Israelita Albert Einstein, São Paulo-SP, Brazil.
• Am. J. Med. 2024 Oct 1; 137 (10): 958965958-965.

ObjectiveWe aimed to evaluate the safety and efficacy of antithrombotic strategies by age in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention in AUGUSTUS.MethodsPatients were stratified into 3 age groups: <65, 65-74, and ≥75 years. Outcomes of interest were major or clinically relevant non-major bleeding, major bleeding, death or rehospitalization, and ischemic events. Treatment effects of apixaban vs. vitamin K antagonist (VKA) and aspirin vs. placebo were assessed across age groups using Cox models.ResultsOf 4614 patients, 1267 (27.5%) were <65, 1802 (39.0%) were 65-74, and 1545 (33.5%) were ≥75 years. Apixaban was associated with lower rates of major or clinically relevant non-major bleeding than VKA (<65: HR 0.69 [0.47-1.00]; 65-74: HR 0.57 [0.43-0.75]; ≥75: HR 0.81 [0.63-1.04]). Death or hospitalization occurred less often with apixaban, regardless of age. No differences were observed in rates of ischemic events between apixaban and VKA according to age. Aspirin was associated with higher rates of bleeding than placebo (<65: HR 1.67 [1.15-2.43]; 65-74: HR 2.32 [1.73-3.10]; ≥75: HR 1.69 [1.31-2.19]). Rates of death or rehospitalization and ischemic events were similar among patients receiving aspirin or placebo across age groups.ConclusionsApixaban was associated with greater absolute reduction in bleeding than VKA in older age groups, reflecting their higher hemorrhagic risk. Aspirin increased bleeding in all age groups vs. placebo. Our findings support the use of apixaban plus a purinergic receptor P2Y12(P2Y12) inhibitor without aspirin in patients with atrial fibrillation and recent acute coronary syndrome/percutaneous coronary intervention, regardless of age.Copyright © 2024 Elsevier Inc. All rights reserved.

36 keywords...

hide…